Health
ESMO Guidelines Discourage Delayed, Discontinued Treatment During the COVID-19 Pandemic – OncLive
Any type of anti-cancer therapy that could impact overall survival should not be discontinued or delayed.
Any type of anti-cancer therapy that could impact overall survival (OS) should not be discontinued or delayed, according to a European Society for Medical Oncology (ESMO) interdisciplinary expert consensus paper on how to manage patients with cancer during the coronavirus disease 2019 (COVID-19) pandemic.1
The guidelines, which were recently published in the Annals of Oncology,2 also discourage classifying all patients with cancer as especially vulnerable to COVID-19, regardless of age, gender,…
-
Noosa News22 hours agoStudents say new facility would be better in rural areas of Queensland
-
General16 hours ago‘We are here for you’: PM to bring help to flood zones
-
General14 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News14 hours agoRates on hold; pressure builds for cuts in May